MA28756B1 - Derives substitues d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de la kinase - Google Patents

Derives substitues d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de la kinase

Info

Publication number: MA28756B1
Authority: MA; Morocco
Prior art keywords: kinase; inhibitors; preparation; substituted derivatives; pharmaceutical use
Prior art date: 2004-07-27

Application number

MA29640A

Other languages

English (en)

Inventor

Hartmut Strobel

Sven Ruf

Dominique Lesuisse

Conception Nemecek

Youssef El-Ahmad

Jacques Mauger

Stefan Guessregen

Kurt Ritter

Jean-Luc Malleron

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-27

Filing date

2007-01-29

Publication date

2007-07-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28756(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-01-29 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2007-07-02 Publication of MA28756B1 publication Critical patent/MA28756B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA29640A 2004-07-27 2007-01-29 Derives substitues d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de la kinase MA28756B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04291903A EP1621535A1 (fr)	2004-07-27	2004-07-27	Dérivés substitués d'urée cyclique, leur préparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number	Publication Date
MA28756B1 true MA28756B1 (fr)	2007-07-02

Family

ID=34931288

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA29640A MA28756B1 (fr)	2004-07-27	2007-01-29	Derives substitues d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de la kinase

Country Status (19)

Country	Link
US (1)	US20080021029A1 (fr)
EP (2)	EP1621535A1 (fr)
JP (1)	JP2008508230A (fr)
KR (1)	KR20070038531A (fr)
CN (1)	CN101010314A (fr)
AR (1)	AR050181A1 (fr)
AU (1)	AU2005266462A1 (fr)
BR (1)	BRPI0513901A (fr)
CA (1)	CA2572970A1 (fr)
EA (1)	EA200700168A1 (fr)
IL (1)	IL180488A0 (fr)
MA (1)	MA28756B1 (fr)
MX (1)	MX2007001025A (fr)
NO (1)	NO20071074L (fr)
PE (1)	PE20060573A1 (fr)
TW (1)	TW200617002A (fr)
UY (1)	UY29038A1 (fr)
WO (1)	WO2006010643A1 (fr)
ZA (1)	ZA200700709B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7354933B2 (en) *	2003-01-31	2008-04-08	Aventis Pharma Sa	Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (fr)	2004-07-27	2006-02-01	Aventis Pharma S.A.	Dérivés d'urées cycliques aminés, leur préparation et utilisation pharmaceutique en tant qu'inhibiteurs de Kinase
FR2896504B1 (fr)	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896503B1 (fr) *	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
ES2380499T3 (es)	2006-11-30	2012-05-14	Kowa Company. Ltd.	Compuesto de Carbinol sustituido
JP5486928B2 (ja) *	2007-02-26	2014-05-07	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックウレアおよびカルバメートインヒビター
EP2183229B1 (fr) *	2007-07-26	2012-04-18	Vitae Pharmaceuticals, Inc.	Synthèse d'inhibiteurs de la 11beta -hydroxystéroïde déshydrogénase de type 1
AR069207A1 (es) *	2007-11-07	2010-01-06	Vitae Pharmaceuticals Inc	Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (fr)	2007-12-11	2009-06-18	Vitae Pharmaceutical, Inc	Inhibiteurs cycliques d'urée de la 11-hydroxystéroïde déhydrogénase 1
TW200934490A (en) *	2008-01-07	2009-08-16	Vitae Pharmaceuticals Inc	Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (fr) *	2008-01-24	2009-07-30	Vitae Pharmaceuticals, Inc.	Carbazate cyclique et inhibiteurs du type semi-carbazide de la 11β-hydroxystéroïde déshydrogénase 1
CA2714532A1 (fr) *	2008-02-11	2009-08-20	Vitae Pharmaceuticals, Inc.	INHIBITEURS 1,3-OXAZEPAN-2-ONE ET 1,3-DIAZEPAN-2-ONE DE LA 11ß-HYDROXYSTEROIDE DESHYDROGENASE (TYPE1)
US8598160B2 (en) *	2008-02-15	2013-12-03	Vitae Pharmaceuticals, Inc.	Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2009117109A1 (fr) *	2008-03-18	2009-09-24	Vitae Pharmaceuticals, Inc.	Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase de type 1
CA2723039A1 (fr)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-beta-hydroxysteroide dehydrogenase 1
JP5451752B2 (ja) *	2008-05-01	2014-03-26	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
ES2421537T3 (es)	2008-05-01	2013-09-03	Vitae Pharmaceuticals Inc	Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
CA2723034A1 (fr)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-beta-hydroxysteroide dehydrogenase 1
DK2324018T3 (da)	2008-07-25	2013-10-14	Boehringer Ingelheim Int	Cykliske inhibitorer af 11 beta-hydroxysteroid dehydrogenase 1
US8846668B2 (en)	2008-07-25	2014-09-30	Vitae Pharmaceuticals, Inc.	Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2393807B1 (fr)	2009-02-04	2013-08-14	Boehringer Ingelheim International GmbH	Inhibiteurs cycliques de la 11beta -hydroxystéroïde déshydrogénase 1
US8051947B2 (en) *	2009-03-12	2011-11-08	E.I. Du Pont De Nemours And Company	Energy absorbing thermoplastic elastomer
TW201039034A (en) *	2009-04-27	2010-11-01	Chunghwa Picture Tubes Ltd	Pixel structure and the method of forming the same
KR20120061771A (ko) *	2009-04-30	2012-06-13	비타이 파마슈티컬즈, 인코포레이티드	11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
US8680093B2 (en)	2009-04-30	2014-03-25	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2440537A1 (fr)	2009-06-11	2012-04-18	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1 basée sur la structure 1,3-oxazinan-2-one
WO2011002910A1 (fr)	2009-07-01	2011-01-06	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1
EP2483406A2 (fr)	2009-09-30	2012-08-08	President and Fellows of Harvard College	Procédés de modulation de l'autophagie par la modulation de produits géniques inhibant l'autophagie
US20110225649A1 (en) *	2010-03-11	2011-09-15	International Business Machines Corporation	Protecting Computer Systems From Malicious Software
WO2011159760A1 (fr)	2010-06-16	2011-12-22	Vitae Pharmaceuticals, Inc.	Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
JP5813106B2 (ja)	2010-06-25	2015-11-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
EA201300522A1 (ru)	2010-11-02	2013-11-29	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтические комбинации для лечения метаболических нарушений
EP2548869A1 (fr) *	2011-07-20	2013-01-23	Cytec Technology Corp.	Procédé de synthèse pour des alkylène urées cycliques substítuées à un atome azote
CA2844783C (fr)	2011-08-16	2019-10-29	Universite Laval	2-imidazolidinones et 2-imidazolones substituees et leur utilisation dans le traitement du cancer
GB201312492D0 (en) *	2013-07-12	2013-08-28	Syngenta Ltd	Herbicidal compounds
CN106170488B (zh)	2014-02-12	2020-09-18	弗门尼舍公司	用于取代的1-苄基-3-(1-(异噁唑-4-基甲基)-1h-吡唑-4-基)咪唑烷-2,4-二酮的合成的改进方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5344575A (en) *	1976-10-01	1978-04-21	Yoshitomi Pharmaceut Ind Ltd	Preparation of hydantoin derivatives
JPS57212180A (en) *	1981-06-19	1982-12-27	Yoshitomi Pharmaceut Ind Ltd	Tetrahydrofuran(thiophene) compound
FR2693461B1 (fr) *	1992-07-08	1994-09-02	Roussel Uclaf	Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) *	1991-01-09	1995-05-02	Roussel Uclaf	Phenylimidazolidines having antiandrogenic activity
SK94393A3 (en) *	1992-09-11	1994-08-10	Thomae Gmbh Dr K	Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
DE4332168A1 (de) *	1993-02-22	1995-03-23	Thomae Gmbh Dr K	Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19540027A1 (de) *	1995-10-27	1997-04-30	Gruenenthal Gmbh	Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
TR199902124T2 (xx) *	1997-03-03	2000-06-21	Boehringer Ingelheim Pharmaceuticals, Inc.	�ltihapl� hastal�klar�n tedavisinde yararl� k��k molek�ller.
DE19732928C2 (de) *	1997-07-31	2000-05-18	Gruenenthal Gmbh	Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
AU2002951247A0 (en) *	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
US7354933B2 (en) *	2003-01-31	2008-04-08	Aventis Pharma Sa	Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) *	2003-01-31	2008-05-30	Aventis Pharma Sa	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1621536A1 (fr) *	2004-07-27	2006-02-01	Aventis Pharma S.A.	Dérivés d'urées cycliques aminés, leur préparation et utilisation pharmaceutique en tant qu'inhibiteurs de Kinase
FR2896504B1 (fr) *	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

2004
- 2004-07-27 EP EP04291903A patent/EP1621535A1/fr not_active Withdrawn
2005
- 2005-07-25 PE PE2005000868A patent/PE20060573A1/es not_active Application Discontinuation
- 2005-07-25 AR ARP050103072A patent/AR050181A1/es unknown
- 2005-07-25 EA EA200700168A patent/EA200700168A1/ru unknown
- 2005-07-25 ZA ZA200700709A patent/ZA200700709B/xx unknown
- 2005-07-25 CA CA002572970A patent/CA2572970A1/fr not_active Abandoned
- 2005-07-25 JP JP2007523040A patent/JP2008508230A/ja active Pending
- 2005-07-25 KR KR1020077002137A patent/KR20070038531A/ko not_active Withdrawn
- 2005-07-25 CN CNA2005800287068A patent/CN101010314A/zh active Pending
- 2005-07-25 BR BRPI0513901-5A patent/BRPI0513901A/pt not_active IP Right Cessation
- 2005-07-25 EP EP05779033A patent/EP1773809A1/fr not_active Withdrawn
- 2005-07-25 WO PCT/EP2005/008722 patent/WO2006010643A1/fr not_active Ceased
- 2005-07-25 MX MX2007001025A patent/MX2007001025A/es not_active Application Discontinuation
- 2005-07-25 AU AU2005266462A patent/AU2005266462A1/en not_active Abandoned
- 2005-07-26 TW TW094125194A patent/TW200617002A/zh unknown
- 2005-07-27 UY UY29038A patent/UY29038A1/es unknown
2007
- 2007-01-01 IL IL180488A patent/IL180488A0/en unknown
- 2007-01-26 US US11/627,515 patent/US20080021029A1/en not_active Abandoned
- 2007-01-29 MA MA29640A patent/MA28756B1/fr unknown
- 2007-02-26 NO NO20071074A patent/NO20071074L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN101010314A (zh)	2007-08-01
IL180488A0 (en)	2007-06-03
NO20071074L (no)	2007-04-27
PE20060573A1 (es)	2006-07-22
EA200700168A1 (ru)	2007-06-29
WO2006010643A1 (fr)	2006-02-02
AU2005266462A1 (en)	2006-02-02
KR20070038531A (ko)	2007-04-10
TW200617002A (en)	2006-06-01
BRPI0513901A (pt)	2008-05-20
JP2008508230A (ja)	2008-03-21
CA2572970A1 (fr)	2006-02-02
AR050181A1 (es)	2006-10-04
UY29038A1 (es)	2006-02-24
MX2007001025A (es)	2007-04-16
US20080021029A1 (en)	2008-01-24
ZA200700709B (en)	2008-11-26
EP1773809A1 (fr)	2007-04-18
EP1621535A1 (fr)	2006-02-01

Publication	Publication Date	Title
MA28756B1 (fr)	2007-07-02	Derives substitues d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de la kinase
MA28732B1 (fr)	2007-07-02	Nouveaux derives d'uree cyclique, leur preparation, et leur uttilisation pharmaceutique comme inhibiteurs de la kinase
FR2850652B1 (fr)	2008-05-30	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MA28753B1 (fr)	2007-07-02	Derives cycliques d'uree substitues par un heterocycle, leur preparation et leur utilisation pharmaceutique en tant qu'inhibiteurs de kinases
MA28941B1 (fr)	2007-10-01	Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896503B1 (fr)	2012-07-13	Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
IL176236A (en)	2015-10-29	Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL192937A0 (en)	2009-02-11	Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same
IL221770A (en)	2015-06-30	Edamantyl acetamide derivatives, the pharmaceutical composition containing them and its use in the preparation of a drug
IL163831A0 (en)	2005-12-18	Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
HUE040046T2 (hu)	2019-02-28	Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
FR2903695B1 (fr)	2008-10-24	Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUP0303146A3 (en)	2007-08-28	3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
MA27366A1 (fr)	2005-06-01	Nouveaux derives de thiophenylglycoside, methodes pour leur production, medicaments contenant lesdits composes et leur utilisation
MA28365A1 (fr)	2006-12-01	Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
FR2868780B1 (fr)	2008-10-17	Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EE05385B1 (et)	2011-02-15	LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
MA28366A1 (fr)	2006-12-01	Derives de piperidinylalkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
FR2896504B1 (fr)	2012-07-13	Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2873690B1 (fr)	2006-10-13	Derives d'oxopiperidine, leur preparation et leur application en therapeutique
FR2880023B1 (fr)	2007-02-23	Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
FR2870846B1 (fr)	2006-08-04	Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1961753A4 (fr)	2009-11-25	Derives de la pirazolopyrimidinone, leur preparation et leur utilisation
FR2873377B1 (fr)	2006-10-13	Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
FR2862967B1 (fr)	2006-08-04	Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique